{"nctId":"NCT00003702","briefTitle":"Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia","startDateStruct":{"date":"1999-06"},"conditions":["Good Prognosis Metastatic Gestational Trophoblastic Tumor","Hydatidiform Mole","Non-Metastatic Gestational Trophoblastic Tumor","Uterine Corpus Choriocarcinoma"],"count":240,"armGroups":[{"label":"Arm I (methotrexate)","type":"EXPERIMENTAL","interventionNames":["Drug: Methotrexate"]},{"label":"Arm II (dactinomycin)","type":"EXPERIMENTAL","interventionNames":["Biological: Dactinomycin"]}],"interventions":[{"name":"Dactinomycin","otherNames":["Actinomycin A IV","Actinomycin C1","ACTINOMYCIN D","Actinomycin I1","Actinomycin IV","Actinomycin X 1","Actinomycin-[thr-val-pro-sar-meval]","Cosmegen","DACT","Dactinomycine","Lyovac Cosmegen","Meractinomycin"]},{"name":"Methotrexate","otherNames":["Abitrexate","Alpha-Methopterin","Amethopterin","Brimexate","CL 14377","CL-14377","Emtexate","Emthexat","Emthexate","Farmitrexat","Fauldexato","Folex","Folex PFS","Lantarel","Ledertrexate","Lumexon","Maxtrex","Medsatrexate","Metex","Methoblastin","Methotrexate LPF","Methotrexate Methylaminopterin","Methotrexatum","Metotrexato","Metrotex","Mexate","Mexate-AQ","MTX","Novatrex","Rheumatrex","Texate","Tremetex","Trexeron","Trixilem","WR-19039"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically proven low-risk gestational trophoblastic neoplasia (persistent hydatidiform mole or choriocarcinoma), defined as 1 of the following:\n\n  * Less than 10% decrease in the beta human chorionic gonadotropin (HCG) titer over 3 weekly titers\n  * Greater than 20% sustained rise in beta HCG titer over two consecutive weeks\n  * Persistently elevated beta HCG titer more than 4 months after initial curettage (greater than 5 mIU/mL minimum)\n  * Histologically proven nonmetastatic choriocarcinoma\n  * Metastases to vagina, parametria, or lung (if no single pulmonary lesion is greater than 2 cm)\n* WHO score 0-6 (not including blood group or CT lung)\n* No histologically confirmed placental site pseudotumor\n* Must have undergone at least 1 uterine curettage\n* Previously untreated disease\n* Performance status - GOG 0-2\n* WBC at least 3,000/mm\\^3\n* Granulocyte count at least 1,500/mm\\^3\n* Platelet count at least 100,000/mm\\^3\n* Bilirubin no greater than 1.5 times upper limit of normal (ULN)\n* SGPT and SGOT no greater than 3 times ULN\n* Alkaline phosphatase no greater than 3 times ULN\n* No significant prior abnormal hepatic function\n* Creatinine no greater than 2.0 mg/dL\n* No significant prior abnormal renal function\n* Not pregnant or nursing\n* Fertile patients must use effective contraception during and for one year after study entry\n* No other prior or concurrent malignancies within the past 5 years except nonmelanomatous skin cancer\n* No prior chemotherapy for gestational trophoblastic neoplasia\n* No concurrent curettage except as needed to control vaginal bleeding or to rule out placental site pseudotumor","healthyVolunteers":false,"sex":"FEMALE","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Response Based on Blood Human Chorionic Gonadotropin (hCG) Assay","description":"Primary outcome is measured as a difference in proportion responding between treatment arms and evaluated using a chi square test. A complete response was defined as a normal hCG sustained over four weekly measurements.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"PRIMARY","title":"Incidence of Adverse Effects (Grade 3 or Higher) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 2.0","description":"Number of participants with a maximum grade of 3 or higher during the treatment period.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With a Decline of hCG on Day 1 of Treatment","description":"Number of patients with a decline in hCG on day 1 of treatment relative to the level at enrollment. A decline is defined as a decrease by 1 or more units between enrollment and treatment start.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":107},"commonTop":["Nausea","Constitutional","Pain","Neutropenia","Hemorrhage"]}}}